Black technology: a super empire spanning two worlds

Chapter 181 [Everyone loves this pie]

The time came to mid-to-late February.

More than 200 people including Chen Shuding arrived in Linzhou City one after another and joined Lingjing Technology. The company hired these talents with high salaries. With the addition of these people, the bioengineering business department could be quickly established and operated.

This also greatly saves time costs. For Xiao Yu, time cost is the most expensive.

In Xiao Yu's eyes, as long as the time cost can be reduced, it is the biggest savings. As for the issue of money investment, it is a minor problem.

On Friday, February 2, Lingjing Technology officially issued an announcement that the company's board of directors passed a resolution.

The company's newly established bioengineering business department has formulated a "three-decade" ultra-long-term plan for monomer organ cloning technology, with each decade as a medium-term plan, and each ten-year medium-term plan further divided into three short-term plans of about three years.

This made everyone realize that Xiao Yu was serious and meant to do things for real, rather than just making gimmicks or playing with concepts or just empty promises.

In addition, the company plans to invest RMB 225 billion in the research and development budget for monomeric organ cloning technology in its first three-year short-term plan.

Chen Shuding and more than 200 other people who came to join the company were also shocked when they saw the company's plan. It was far beyond their expectations. They had never thought that Xiao Yu's investment and support in this field would be so great that he actually formulated an ultra-long-term plan of thirty years.

This is equivalent to telling them that they can work at Lingjing Technology until retirement.

Moreover, the intensity of the investment has far exceeded their expectations. A three-year short-term plan is expected to invest 225 billion in R&D expenses. If this number is quantified, the total investment over the next 2250 years will reach billion, which is undoubtedly an astronomical investment.

Chen Shuding and others were all very excited about this, as they no longer had to worry about research and development funds.

If you can’t spend it all, you can’t spend it all.

Because research in the field of bioengineering is relatively inexpensive, the exposure of the "gene-edited baby" incident that occurred five years ago in 2018 caused an uproar inside and outside the industry. The leaders of the incident did not spend much money and did it secretly.

Bioengineering research can sometimes be done at a very low cost, without the need for overly expensive equipment. The upper limit is of course very high, but the characteristic is that the lower limit is also very low, so low that research can be carried out with just a few culture dishes, test tubes and some biological samples, and even one can extract one's own somatic cells as research samples.

Unlike other industries, such as chips, the lower limit cannot be too low. Whether it is equipment or manpower, it cannot be done without a certain scale, and it is even more impossible for a single individual.

On the contrary, those who do biological research can set up a laboratory in a room by themselves to conduct research.

From this, it can be seen that Xiao Yu allocated a huge budget of 225 billion to the company's bioengineering business department for a short-term plan of about three years, which confused Chen Shuding and others.

Suddenly we are eating so well, where did we get such sufficient funds in the past?
However, this incident did not have much effect on boosting Lingjing Technology's stock price in the capital market. When the announcement was made today, the company's stock price closed down -3.59% to 191.43 yuan, and its market value fell to 16.62 trillion yuan.

Compared with its historical highest price of 239.89 yuan, Lingjing Technology's current stock price has fallen by -20.20%, and there is still no sign of stabilization.

The company has not had any negative news during this period. The main factor for this adjustment is the normal profit-taking of profitable funds and the overall poor environment of the stock market. The market index has now entered a downward channel.

Under such circumstances, it is unrealistic for super large-cap stocks like Lingjing Technology to strengthen again unless there is an epic positive boost that exceeds expectations.

The company announced that it would enter the field of modern bioengineering and develop single-organ cloning technology. This matter has also received support from people from all walks of life, but its impact on stock price fluctuations is neither negative nor positive.

Investors believe that it is a positive in the medium and long term, recognize the company's strong innovation capabilities, and are willing to give it time to wait. The real reaction to the stock price depends on the progress of the next research. If the research on single-organ cloning technology is hindered or even very pessimistic, such a large investment may be wasted. After forming such an expectation, the stock price will definitely fall.

But on the other hand, if the progress is encouraging, or even exceeds expectations, the company will have a new support point, which will inevitably be reflected in an increase in the stock price, because once single-organ cloning technology is put into clinical use, it will have incredibly broad prospects.

……

That afternoon, Xiao Yu logged into his personal Weibo and posted a dynamic article, further boosting the expectations of people from all walks of life for monomeric organ cloning technology.

【We know that one of the core processes of aging is cell senescence. As we age, cells undergo multiple divisions and their telomeres gradually shorten. Telomeres are like "safety caps" at the ends of cell chromosomes, playing a key role in protecting gene integrity.

When telomeres are worn to a certain extent, cells will start the aging process, stop dividing, and cause organ function decline.

Single organ cloning technology brings hope for breaking the shackles of aging. By cloning young and healthy organs to replace aged and diseased organs, the cell population can be fundamentally renewed and the cell aging clock can be reset.

Taking the liver as an example, when the aging liver is replaced by a cloned new liver, the liver cells are able to "rejuvenate" and efficiently perform complex physiological functions such as metabolism and detoxification again, continuously injecting vitality into the body.

From a molecular perspective, the activation of telomerase is the key factor, which can replenish telomere length during cell division and maintain the youthful state of cells.

The activity of telomerase in normal somatic cells is strictly regulated and is at a low level. In the process of cloned organ cultivation, it is hoped that the telomerase gene can be precisely regulated so that it is moderately activated in the transplanted organs, ensuring the continued proliferation of cells, thereby delaying the overall aging process and allowing the body's organs to work together and maintain vigorous metabolic function.

Many fatal diseases are "stumbling blocks" on the road to longevity for humans. Single organ cloning technology has shown unparalleled potential in conquering these diseases.

Take diabetes as an example. This global chronic disease originates from damage to pancreatic beta cells and disordered insulin secretion, which causes high blood sugar levels and long-term damage to multiple organs such as the heart, kidneys, and eyes.

Traditional treatments, such as insulin injections, can only relieve symptoms but cannot cure the disease.

The monomer organ cloning technology takes a different approach. By collecting the patient's own cells, a fully functional pancreas or islet tissue can be cloned, thereby achieving autonomous and precise regulation of insulin secretion, correcting sugar metabolism disorders at the root, blocking the chain of disease deterioration, and avoiding a series of fatal complications caused by diabetes.

Let’s look at heart disease. As the world’s number one killer, myocardial infarction, heart failure, etc. are often caused by irreversible damage to myocardial cells, impaired heart pumping function, and insufficient blood supply to the whole body.

Monomer organ cloning technology cultivates cardiomyocytes or myocardial tissue sheets in vitro and uses biological scaffolds to precisely transplant them to the damaged myocardium. These newly born cardiomyocytes are integrated into the heart tissue, which can enhance the heart's contraction and relaxation functions, reshape the heart's vitality, light up the dawn of life for patients with heart disease, and solve the problem of the disease.

In short, on the road to achieving human longevity, single organ cloning technology has unparalleled potential in both delaying aging and conquering diseases, and the imagination space is broad. 】

Whether it should be said or not, whether it can be realized or not is not discussed for now.

But Xiao Yu keeps drawing big cakes, one after another. Even though everyone knows he is drawing big cakes, they still like to eat them, whether they are the ordinary people in the middle and lower classes or the wealthy and powerful social elites in the upper class. All groups like to eat them, and they eat them with relish and enjoy themselves very much.

Because few people can resist the temptation of living for more than 200 years. This kind of attraction is absolutely fatal.

……

(End of this chapter)